FDA OKs presurgical use of Roche's breast cancer drug Perjeta

10/1/2013 | Bloomberg · Reuters

The FDA approved the use of Roche Holding's Perjeta, or pertuzumab, to reduce tumor size before surgery in patients with HER2-positive, early-stage breast cancer. The drug would be used in combination with Roche's older breast cancer treatment Herceptin and chemotherapy. The approval makes Perjeta the first presurgical treatment for breast cancer.

View Full Article in:

Bloomberg · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care